Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
Intravenous, 4 milligrams, once every 3 to 4 weeks.
The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.
Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.
The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.
Zoledronic acid solution should be given as a single intravenous infusion in no less than 15 minutes.